Docetaxel — CPB 0956 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0956 governing docetaxel coverage, effective December 6, 2025. Here's what billing teams need to know before submitting claims under J9171, J9172, or J9174.

Aetna's updated docetaxel coverage policy under CPB 0956 Aetna system covers 17 cancer indications — from prostate and breast cancer to rare diagnoses like Ewing sarcoma and anaplastic thyroid carcinoma. The policy covers three docetaxel formulations billed under HCPCS codes J9171, J9172, and J9174, administered via intravenous infusion reported with CPT codes 96413, 96414, and 96415. If your oncology or infusion billing team handles commercial Aetna claims, this policy directly affects your prior authorization workflow and medical necessity documentation.

Quick-Reference Table

Aetna Docetaxel Coverage Criteria and Medical Necessity Requirements 2025

Aetna considers docetaxel medically necessary across 17 distinct cancer categories. The breadth here is real — this isn't a narrow single-indication policy. But breadth doesn't mean automatic approval. Each indication carries its own criteria, and billing without matching the right clinical scenario to the right documentation will get you a claim denial.

The covered formulations are Beizray (J9174), Docivyx (J9172), Taxotere, and generic docetaxel (J9171). These are not interchangeable for billing purposes. J9172 and J9174 each have their own HCPCS codes because Aetna — and the code set — treats them as distinct products. Bill the wrong code for the formulation administered, and you've created a mismatch that auditors will flag.

Medical necessity for breast cancer has the most complex criteria tree in this policy. For HER2-negative recurrent, unresectable, or metastatic disease, docetaxel is covered as a single agent or in combination with capecitabine. For HER2-positive disease in the same settings, docetaxel must be used in a specific regimen: either with pertuzumab and trastuzumab, or with trastuzumab alone (with or without endocrine therapy). Adjuvant and preoperative breast cancer indications are also covered. There's also a taxane-substitution pathway — docetaxel can be approved in place of paclitaxel or albumin-bound paclitaxel when medical necessity supports it.

For prostate cancer, the coverage policy aligns with standard-of-care use but requires documentation that supports the specific disease setting. The same applies to non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) — both covered, but the clinical record needs to match the indication you're billing.

Several less common indications are explicitly covered under this policy. Anal squamous cell carcinoma must be metastatic or unresectable locally recurrent. Bone cancers — Ewing sarcoma and osteosarcoma — must be relapsed, progressive, refractory, or metastatic. Small bowel adenocarcinoma coverage applies to advanced or metastatic disease only. Anaplastic thyroid carcinoma is covered; differentiated thyroid cancer is not listed.

Cervical cancer coverage applies to subsequent treatment of advanced, persistent, recurrent, or metastatic disease, either as a single agent or in combination with carboplatin. Ovarian cancer coverage includes a broad range of histologic subtypes: epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, low-grade endometrioid, low-grade serous, mucinous, malignant sex-cord stromal, and recurrent malignant germ cell tumors.

Prior authorization requirements apply to this policy for commercial plans. Your PA request needs to specify the formulation, the regimen, and the clinical scenario — vague requests get denied or returned for more information.

Aetna Docetaxel Exclusions and Non-Covered Indications

The policy summary as provided does not enumerate a standalone exclusion list in the truncated section. However, the structure of CPB 0956 means coverage is limited to the indications explicitly listed. If a clinical scenario doesn't appear in the covered indications — for example, differentiated thyroid carcinoma, or a soft tissue sarcoma subtype not listed — Aetna will deny on medical necessity grounds.

The real issue here is the specificity of the disease-state criteria. A claim for docetaxel in Ewing sarcoma that doesn't document relapsed, progressive, or metastatic status will not meet the criteria. An ovarian cancer claim that lists a histology not included in the policy's subtype list faces the same problem. Your documentation has to match the policy language — not just the diagnosis.

Soft tissue sarcoma coverage is worth a close read. The policy names specific subtypes: angiosarcoma, extremity/body wall, head/neck, retroperitoneal/intra-abdominal, pleomorphic rhabdomyosarcoma, dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous transformation, dedifferentiated chordoma, solitary fibrous tumor, dedifferentiated liposarcoma, and epithelioid hemangioendothelioma. A sarcoma subtype not on that list is not covered, even if docetaxel is used clinically.

Coverage Indications at a Glance

Aetna Docetaxel Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Docetaxel Under CPB 0956

Covered HCPCS Codes (When Selection Criteria Are Met)

Other HCPCS Codes Referenced in CPB 0956 (Paclitaxel — Related Policy Context)

The paclitaxel codes appear in CPB 0956 because the policy includes a taxane-substitution pathway for breast cancer. If your team is documenting medical necessity for docetaxel as a substitute for paclitaxel (J9267) or albumin-bound paclitaxel (J9264), the clinical rationale for the switch needs to be explicit in the record.

Key ICD-10-CM Diagnosis Codes

CPB 0956 maps to 486 ICD-10-CM codes. The table below covers the primary cancer categories from the policy data. Confirm the full code list in the policy for your specific patient population.

For the full list of 486 ICD-10-CM codes mapped to CPB 0956, access the complete policy at PayerPolicy CPB 0956. Your coding team should run a crosswalk between your active oncology diagnosis codes and the full ICD-10 list before the December 6, 2025 effective date — particularly for the less common indications where code specificity matters most.